<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25081" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methyldopa</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Sharda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25081.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Methyldopa is a medication used in the management and treatment of hypertension. It is in the centrally acting anti-hypertensive class of drugs. This activity reviews the indications, actions, and contraindications for methyldopa as a valuable agent in the management of hypertension. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the inter-professional team in the management of patients with hypertension and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of methyldopa.</p></list-item><list-item><p>Describe the adverse effects of methyldopa.</p></list-item><list-item><p>Review the appropriate monitoring for toxicity of methyldopa.</p></list-item><list-item><p>Outline inter-professional team strategies for improving care coordination and communication to advance methyldopa and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25081&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25081">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25081.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Methyldopa is a centrally acting sympatholytic agent used in the treatment of hypertension. Since its introduction in 1960, the drug quickly became a leading antihypertensive, but its use has decreased markedly, replaced by better-tolerated alternatives. It is still in use in developing countries due to its low cost.&#x000a0;This drug is also useful in pregnancy because it has no teratogenic effects.<xref ref-type="bibr" rid="article-25081.r1">[1]</xref></p>
      </sec>
      <sec id="article-25081.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Alpha-methyldopa is converted to methyl norepinephrine centrally to decrease the adrenergic outflow by alpha-2 agonistic action from the central nervous system, leading to reduced total peripheral resistance and decreased systemic blood pressure. Alpha-2 agonistic activity does not affect cardiac output or renal blood flow.; hence, this drug is useful in hypertensive patients with renal insufficiency.</p>
      </sec>
      <sec id="article-25081.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Methyldopa is generically available as a single ingredient in 125, 250, or 500 mg tablets.<xref ref-type="bibr" rid="article-25081.r2">[2]</xref>&#x000a0;Fixed-dose combinations with thiazides are also on the market. The recommended dose in adults is 500 mg to 2 g daily. Clinicians should discontinue the drug if any side effects manifest in the patient.</p>
        <p>IV infusion in the form of methyldopa hydrochloride is available. The drug gets diluted in 5% dextrose, and the required dose is added to 100 mL of 5% dextrose in water injection and administered slowly over 30&#x000a0;to 60 minutes. IM or subcutaneous administration is not a recommendation due to unpredictable absorption.<xref ref-type="bibr" rid="article-25081.r3">[3]</xref><xref ref-type="bibr" rid="article-25081.r4">[4]</xref></p>
        <p>Despite its popularity during the 70s, other alternatives have replaced methyldopa as a mainstay for the treatment of hypertension. Methyldopa remains a second-line treatment to be used safely during pregnancy.<xref ref-type="bibr" rid="article-25081.r5">[5]</xref><xref ref-type="bibr" rid="article-25081.r6">[6]</xref></p>
      </sec>
      <sec id="article-25081.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Sedation</p>
          </list-item>
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
        </list>
        <p>Rare yet clinically fatal adverse effects include<xref ref-type="bibr" rid="article-25081.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemolytic anemia (Coombs positive)</p>
          </list-item>
          <list-item>
            <p>Lupus-like syndrome</p>
          </list-item>
          <list-item>
            <p>Myocarditis</p>
          </list-item>
          <list-item>
            <p>Pancreatitis</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Reversible leukopenia</p>
          </list-item>
          <list-item>
            <p>Involuntary choreoathetotic movements</p>
          </list-item>
          <list-item>
            <p>Weight gain</p>
          </list-item>
          <list-item>
            <p>Rebound hypertension</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25081.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Active hepatic disease&#x000a0;<xref ref-type="bibr" rid="article-25081.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Liver disorders due to previous therapy</p>
          </list-item>
          <list-item>
            <p>Direct Coombs positive hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>Significant drug history of MAO inhibitor therapy</p>
          </list-item>
          <list-item>
            <p>Pheochromocytoma</p>
          </list-item>
          <list-item>
            <p>Known hypersensitivity to methyldopa in any form</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25081.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>50% of the dose absorbed attains peak plasma concentrations in approximately 3&#x000a0;to 6 hours.</p>
          </list-item>
          <list-item>
            <p>A maximum reduction in blood pressure occurs in 4&#x000a0;to 6 hours following oral administration.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Following IV administration, hypotensive lasts for about 10&#x000a0;to 16 hours.</p>
          </list-item>
        </list>
        <p>
<bold>Distribution</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The drug is lipid-soluble and crosses the blood-brain barrier with weak binding to plasma proteins.</p>
          </list-item>
          <list-item>
            <p>Its primary metabolite has more plasma protein binding as compared to the drug.</p>
          </list-item>
          <list-item>
            <p>Conjugates formed after oral administration are acid labile and are delectable in small amounts after intravenous administration.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The apparent volume of distribution ranges between&#x000a0;0.19 to 0.32L/kg and the total volume of distribution between&#x000a0;0.41 to 0.72L/kg.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Metabolism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Methyldopa gets metabolized to alpha-methylnorepinephrine, the active metabolite.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The drug is also metabolized extensively in the liver to its sulfate conjugate.</p>
          </list-item>
        </list>
        <p>
<bold>Elimination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Excretion of 70% of the drug is via urine in the form of parent drug and metabolite.</p>
          </list-item>
          <list-item>
            <p>Unabsorbed drug is excreted in feces unchanged.</p>
          </list-item>
          <list-item>
            <p>Excretion is slow in patients with renal failure, leading to the accumulation of the drug and its metabolites.<xref ref-type="bibr" rid="article-25081.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Monitoring</bold>
</p>
        <p>Information about the adverse effects and pharmacokinetic principles of the drug is crucial in therapeutic monitoring. After initiation of treatment, periodic testing of hemoglobin, hematocrit, and the red blood cell count is necessary to rule out hemolytic anemia. Direct Coombs test is reported positive, usually after 6&#x000a0;to 12 months of therapy, but rarely results in fatal hemolytic anemia. Discontinuance of drug reverses results within weeks to months.</p>
        <p>Liver function tests are necessary for increased serum concentrations of alkaline phosphatase, aminotransferases, and bilirubin. Hepatic dysfunction may represent a hypersensitivity reaction. Therefore, a&#x000a0;periodic assessment of hepatic function is important during the first 6&#x000a0;to 12 weeks of therapy. Abnormal liver function test results require discontinuation of the drug. The drug is contraindicated in active hepatic disease.</p>
      </sec>
      <sec id="article-25081.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Methyldopa overdose reports are exceedingly rare. Clinical manifestations include coma, hypothermia, hypotension, bradycardia, and dry mouth. In addition, prolonged, severe hypotension, along with marked renal potassium loss necessitating IV infusion of norepinephrine and vigorous potassium replacement therapy for almost two days, was reported.</p>
        <p>
<bold>Hepatotoxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic use of methyldopa is associated with mild and transient elevations in serum aminotransferase levels that resolve after discontinuation of the medication.</p>
          </list-item>
          <list-item>
            <p>Hepatic injury is rather uncommon and may appear within weeks or months to years after initiation of drug therapy.</p>
          </list-item>
          <list-item>
            <p>An acute injury demonstrates elevated levels of ALT and AST (5-to 100-fold). Most patients become jaundiced with symptoms resembling those of viral hepatitis. Liver biopsy shows hepatitis-like features, and re-exposure can lead to severe hepatitis and death.</p>
          </list-item>
          <list-item>
            <p>The chronic injury clinically resembles autoimmune hepatitis with marked elevations in liver enzymes, increases in IgG, and high titers of ANA antibodies. In addition, cirrhosis and end-stage liver disease can occur if drug therapy continues.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Granulomatous hepatitis can also occur with methyldopa therapy associated with systemic symptoms.</p>
          </list-item>
          <list-item>
            <p>The disease resolves slowly with the discontinuation of the drug.<xref ref-type="bibr" rid="article-25081.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hematologic Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Positive Coombs' test shows within a few weeks of initiation of drug therapy, which rarely leads to fatal hemolytic anemia.</p>
          </list-item>
          <list-item>
            <p>Discontinuation of the drug promptly resolves the anemia, along with the use of corticosteroids.<xref ref-type="bibr" rid="article-25081.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25081.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of drug overdose requires an interprofessional team of healthcare professionals, including pharmacists, nurses, laboratory technologists, and several physicians in different specialties. Absent proper management, morbidity and mortality from methyldopa overdose are high. Therefore, the moment the triage nurse has admitted a patient with methyldopa overdose, the emergency department clinician is responsible for coordinating the care, which includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ordering drug level testing in the blood and/or urine.</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs and symptoms of jaundice, fever, drowsiness or sedation, and other preexisting disorders.</p>
          </list-item>
          <list-item>
            <p>The pharmacist should check the medication record to verify dosing and administration were correct.</p>
          </list-item>
          <list-item>
            <p>Nursing should review the medicine administration record to ensure there were no administration errors.</p>
          </list-item>
          <list-item>
            <p>Performing various maneuvers to help limit the absorption of the drug in the body.</p>
          </list-item>
          <list-item>
            <p>Consult with the pharmacist about the use of activated charcoal. [Level 1]</p>
          </list-item>
          <list-item>
            <p>Obtain a consult with a toxicologist and nephrologist on further management, which may include dialysis.</p>
          </list-item>
          <list-item>
            <p>Consult with the radiologist about imaging tests to ensure that the patient has not swallowed any drug packages.</p>
          </list-item>
          <list-item>
            <p>Consultation with the intensivist about ICU care and monitoring while in hospital.</p>
          </list-item>
        </list>
        <p>The management of methyldopa overdose does not stop in the emergency department. Following patient stabilization, one has to determine how and why the patient overdosed. Consult with a mental health counselor if this was an intentional act and assess risk factors for-self harm. Only by functioning as an interprofessional team can the morbidity of methyldopa overdose be decreased. The long-term outcomes for drug therapy include prescribing better-tolerated drugs within a therapeutic range. [Level 2]</p>
        <p>Patients should understand the importance of informing clinicians of existing or contemplated concomitant therapy or concurrent diseases. The importance of informing clinicians about a current or planned pregnancy plays a vital role in improving outcomes.&#x000a0;With an interprofessional team approach to methyldopa therapy, successful results with minimal adverse events are achievable. [Level 5]</p>
      </sec>
      <sec id="article-25081.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25081&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25081">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25081/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25081">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25081.s11">
        <title>References</title>
        <ref id="article-25081.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molvi</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Mir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Jabeen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa.</article-title>
            <source>Arch Gynecol Obstet</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>285</volume>
            <issue>6</issue>
            <fpage>1553</fpage>
            <page-range>1553-62</page-range>
            <pub-id pub-id-type="pmid">22249781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mah</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Tejani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Musini</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Methyldopa for primary hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2009</year>
            <month>Oct</month>
            <day>07</day>
            <volume>2009</volume>
            <issue>4</issue>
            <fpage>CD003893</fpage>
            <pub-id pub-id-type="pmid">19821316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Initial Treatment of Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>15</day>
            <volume>378</volume>
            <issue>7</issue>
            <fpage>636</fpage>
            <page-range>636-644</page-range>
            <pub-id pub-id-type="pmid">29443671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Folic</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Varjacic</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Folic</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Effects of methyldopa and nifedipine on uteroplacental and fetal hemodynamics in gestational hypertension.</article-title>
            <source>Hypertens Pregnancy</source>
            <year>2012</year>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-9</page-range>
            <pub-id pub-id-type="pmid">21219124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muttukrishna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jauniaux</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders.</article-title>
            <source>PLoS One</source>
            <year>2008</year>
            <month>Jul</month>
            <day>23</day>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>e2766</fpage>
            <pub-id pub-id-type="pmid">18648513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <chapter-title>Methyldopa</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myhre</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rugstad</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of methyldopa.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1982</year>
            <season>May-Jun</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-33</page-range>
            <pub-id pub-id-type="pmid">7047042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25081.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Gomersall</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Overdose of methyldopa, indapamide and theophylline resulting in prolonged hypotension, marked diuresis and hypokalaemia in an elderly patient.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>977</fpage>
            <page-range>977-9</page-range>
            <pub-id pub-id-type="pmid">19623566</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
